NEW YORK – Castle Biosciences reported after the close of the market on Monday that its second quarter revenues rose 18 percent year over year.
For the three months ended June 30, the skin cancer diagnostics company reported revenues of $12.7 million, up from $10.7 million a year earlier, and beating the average Wall Street estimate of $8.8 million.